Cytokinetics (NASDAQ:CYTK) on 28 march announced that the expansion phase of the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure, or COSMIC-HF, has opened to enrollment. COSMIC-HF is a Phase II double-blind, randomized, placebo-controlled, multicenter clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosing orally in patients with heart failure and left ventricular systolic dysfunction Cytokinetics, Inc. (NASDAQ:CYTK) shares after opening at $9.47 moved to $9.59 on last trade day and at the end of the day closed at $8.85. Company price to sales ratio in past twelve months was calculated as 10.44 and price to cash ratio as 4.11. Cytokinetics, Inc. (NASDAQ:CYTK) showed a negative weekly performance of -0.34%.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was a big mover last session with its shares rising 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares fell -9.39% in last trading session and ended the day on $49.89. RARE return on equity ratio is recorded as 135.70% and its return on assets is -75.50%.
The board of directors of Oxygen Bio therapeutics Inc. (NASDAQ:OXBT) adopted a resolution effective April 3, 2014 appointing Gerald T. Proehl as a director. Mr. Proehl was the designee selected by Phyxius Pharma, Inc. Stockholders and his appointment as a director consummated one of the terms of the Phyxius Acquisition. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) shares moved down -5.63% in last trading session and was closed at $4.69, while trading in range of $4.46 – $4.99. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) year to date (YTD) performance is 4.22%.
CEL-SCI Corporation (NYSEMKT:CVM) announced it has expanded its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine in the U.S. with the addition of a new site in Scottsdale, Arizona. CEL-SCI Corporation (NYSEMKT:CVM) weekly performance is -20.92%. On last trading day company shares ended up $1.21. CEL-SCI Corporation (NYSEMKT:CVM) distance from 50-day simple moving average (SMA50) is -10.20%. Analysts mean target price for the company is $7.00.